FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1592123850> ?p ?o ?g. }

• W1592123850 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAHypoxia (low oxygen conditions) in prostate tumors is associated with aggressive phenotype and poor prognosis. Also, hypoxia is considered the first major challenge faced by growing mass of neoplastic cells, as cells in hypoxic areas are surrounded by metabolic waste, acidic pH and necrotic cells. To overcome these hostile conditions, tumor cells activate transcriptional machinery leading to neo-angiogenesis, altered metabolism and selection of resistant clones. This suggests that prostate cancer (PCa) growth and progression could be prevented via targeting hypoxia-induced signaling. Here, we analyzed silibinin effect on hypoxia-induced proliferation, angiogenesis and metabolic changes in human PCa cells both in vitro and in vivo. Silibinin inhibited LNCaP cells clone formation (exposed to 1% O2 for 48 hrs and then returned to normoxic culture conditions) by 90-100% at 25-50 µM doses. Under similar hypoxic conditions in 22Rv1 cells, silibinin inhibited the clone formation by 63-77% at 25-50 µM doses. Importantly, conditioned media collected from PCa cells under hypoxic conditions (1% O2 for 24 hrs) induced tube formation by human umbilical vein endothelial cells (HUVEC) on matrigel, whereas conditioned media from silibinin-treated hypoxic PCa cells or silibinin addition in hypoxic-conditioned media abrogated HUVEC tube formation. Interestingly, we observed higher lipid accumulation in LNCaP cells under hypoxia, which was decreased (∼70%) by silibinin. Molecular analyses showed that silibinin decreases hypoxia-induced HIF-1α expression without affecting HIF-1β in PCa cells. Furthermore, silibinin increased the level of FIH (factor inhibiting HIF) and prolyl-hydroxylase 2, involved in HIF-1α degradation. Also, silibinin decreased the level of phosphorylated mTOR and ERK1/2 in PCa cells under hypoxia, and strongly inhibited lipid synthesis via activating AMP-activated protein kinase and decreasing acetyl Co A carboxylase, fatty acid synthase, acetyl Co A synthetase, fatty-acyl Co A synthetase and lipin expression. In vivo, silibinin effect on hypoxia-induced proliferation, angiogenesis and metabolism was analyzed in 22Rv1 xenograft model. Mice with established 22Rv1 tumors were imaged at base-line as well as 6 and 15 days following silibinin administration (200 mg/kg body weight) by diffusion weighted (DWI), dynamic contrast enhanced (DCE)-MRI and 18FDG-PET. At the study end, endogenous tumor metabolites were assed by NMR and various biomarkers by IHC. In vivo results showed that silibinin feeding reduced the tumor volume (by 47%), inhibited HIF-1α signaling, decreased proliferation and angiogenesis (DCE-MRI), induced apoptotic death and modulated tumor metabolism (PET and NMR). Together, these findings further support silibinin usefulness in PCa prevention through inhibiting hypoxia-induced proliferation, angiogenesis and lipogenesis.Citation Format: Gagan Deep, Anand M. Ramteke, Dhanya K. Nambiar, Anil K. Jain, Natalie J. Serkova, Chapla Agarwal, Rajesh Agarwal. Silibinin inhibits hypoxia-induced proliferation, angiogenesis and lipogenesis in prostate cancer cells both in vitro and in vivo. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4114. doi:10.1158/1538-7445.AM2014-4114" @default.
• W1592123850 created "2016-06-24" @default.
• W1592123850 creator A5007029060 @default.
• W1592123850 creator A5017221987 @default.
• W1592123850 creator A5025904775 @default.
• W1592123850 creator A5027734680 @default.
• W1592123850 creator A5048444823 @default.
• W1592123850 creator A5059572873 @default.
• W1592123850 creator A5065541067 @default.
• W1592123850 date "2014-09-30" @default.
• W1592123850 modified "2023-09-27" @default.
• W1592123850 title "Abstract 4114: Silibinin inhibits hypoxia-induced proliferation, angiogenesis and lipogenesis in prostate cancer cells both in vitro and in vivo" @default.
• W1592123850 doi "https://doi.org/10.1158/1538-7445.am2014-4114" @default.
• W1592123850 hasPublicationYear "2014" @default.
• W1592123850 type Work @default.
• W1592123850 sameAs 1592123850 @default.
• W1592123850 citedByCount "0" @default.
• W1592123850 crossrefType "proceedings-article" @default.
• W1592123850 hasAuthorship W1592123850A5007029060 @default.
• W1592123850 hasAuthorship W1592123850A5017221987 @default.
• W1592123850 hasAuthorship W1592123850A5025904775 @default.
• W1592123850 hasAuthorship W1592123850A5027734680 @default.
• W1592123850 hasAuthorship W1592123850A5048444823 @default.
• W1592123850 hasAuthorship W1592123850A5059572873 @default.
• W1592123850 hasAuthorship W1592123850A5065541067 @default.
• W1592123850 hasConcept C121608353 @default.
• W1592123850 hasConcept C126322002 @default.
• W1592123850 hasConcept C134018914 @default.
• W1592123850 hasConcept C141359234 @default.
• W1592123850 hasConcept C150903083 @default.
• W1592123850 hasConcept C178790620 @default.
• W1592123850 hasConcept C185592680 @default.
• W1592123850 hasConcept C207001950 @default.
• W1592123850 hasConcept C2777130413 @default.
• W1592123850 hasConcept C2778608917 @default.
• W1592123850 hasConcept C2779723316 @default.
• W1592123850 hasConcept C2780192828 @default.
• W1592123850 hasConcept C2780394083 @default.
• W1592123850 hasConcept C4733338 @default.
• W1592123850 hasConcept C502942594 @default.
• W1592123850 hasConcept C540031477 @default.
• W1592123850 hasConcept C71924100 @default.
• W1592123850 hasConcept C7836513 @default.
• W1592123850 hasConcept C86803240 @default.
• W1592123850 hasConcept C96232424 @default.
• W1592123850 hasConceptScore W1592123850C121608353 @default.
• W1592123850 hasConceptScore W1592123850C126322002 @default.
• W1592123850 hasConceptScore W1592123850C134018914 @default.
• W1592123850 hasConceptScore W1592123850C141359234 @default.
• W1592123850 hasConceptScore W1592123850C150903083 @default.
• W1592123850 hasConceptScore W1592123850C178790620 @default.
• W1592123850 hasConceptScore W1592123850C185592680 @default.
• W1592123850 hasConceptScore W1592123850C207001950 @default.
• W1592123850 hasConceptScore W1592123850C2777130413 @default.
• W1592123850 hasConceptScore W1592123850C2778608917 @default.
• W1592123850 hasConceptScore W1592123850C2779723316 @default.
• W1592123850 hasConceptScore W1592123850C2780192828 @default.
• W1592123850 hasConceptScore W1592123850C2780394083 @default.
• W1592123850 hasConceptScore W1592123850C4733338 @default.
• W1592123850 hasConceptScore W1592123850C502942594 @default.
• W1592123850 hasConceptScore W1592123850C540031477 @default.
• W1592123850 hasConceptScore W1592123850C71924100 @default.
• W1592123850 hasConceptScore W1592123850C7836513 @default.
• W1592123850 hasConceptScore W1592123850C86803240 @default.
• W1592123850 hasConceptScore W1592123850C96232424 @default.
• W1592123850 hasLocation W15921238501 @default.
• W1592123850 hasOpenAccess W1592123850 @default.
• W1592123850 hasPrimaryLocation W15921238501 @default.
• W1592123850 hasRelatedWork W1928862566 @default.
• W1592123850 hasRelatedWork W1987340528 @default.
• W1592123850 hasRelatedWork W1992154419 @default.
• W1592123850 hasRelatedWork W2029086576 @default.
• W1592123850 hasRelatedWork W2079632755 @default.
• W1592123850 hasRelatedWork W2079998038 @default.
• W1592123850 hasRelatedWork W2087407198 @default.
• W1592123850 hasRelatedWork W2093782234 @default.
• W1592123850 hasRelatedWork W2093855358 @default.
• W1592123850 hasRelatedWork W2115369017 @default.
• W1592123850 hasRelatedWork W2168429202 @default.
• W1592123850 hasRelatedWork W2320039224 @default.
• W1592123850 hasRelatedWork W2565588562 @default.
• W1592123850 hasRelatedWork W2587478484 @default.
• W1592123850 hasRelatedWork W2740684068 @default.
• W1592123850 hasRelatedWork W2788745127 @default.
• W1592123850 hasRelatedWork W2804008709 @default.
• W1592123850 hasRelatedWork W2901168016 @default.
• W1592123850 hasRelatedWork W2988802497 @default.
• W1592123850 hasRelatedWork W3031110815 @default.
• W1592123850 isParatext "false" @default.
• W1592123850 isRetracted "false" @default.
• W1592123850 magId "1592123850" @default.
• W1592123850 workType "article" @default.